Balance & Vestibular✅ Deal Signed — MedBalance GmbH

Exclusive distribution: India, UAE, Thailand, Singapore, Bangladesh, Brazil · 3-year agreement

Markets

Active

$1.08M

Y1 Target

Each row = a target market. Each column = a pipeline stage. Click any cell to open that stage.

Market	Reg / Class	Timeline	Y1 Rev	Market Intel	Dossier	Reg Strategy	GTM Plan	Registration	Sales Ramp	Priority
🇮🇳India	CDSCO Class B	12–18 mo	$480K Y1	✓	✓	●	●	●	○	High
🇦🇪UAE	MOHAP Class IIa	6–9 mo	$216K Y1	✓	●	○	○	○	○	High
🇹🇭Thailand	Thai FDA Class 2	14–18 mo	$96K Y2	✓	○	○	○	○	○	Medium
🇸🇬Singapore	HSA Class B	4–6 mo	$84K Y1	✓	○	○	○	○	○	Medium
🇧🇩Bangladesh	DGDA Import	18–24 mo	$36K Y3	✓	○	○	○	○	○	Watch
🇧🇷Brazil	ANVISA Class III	18–24 mo	$60K Y3	○	○	○	○	○	○	Watch

AI Projected

$1.08M

Year 1 (India + UAE + SG)

$1.8M

Year 2 (+Thailand)

$2.88M

Year 3 (+BD + BR)

✦ AI Launch Strategy

→India + UAE are critical path — both active, both need Hindi/Arabic IFU resolved urgently.

→Singapore has fastest regulatory pathway (4–6 months) — can generate early revenue while India processes.

→Thailand and Bangladesh should run in parallel — start ASEAN dossier preparation now to minimize delays.